Glenmark Pharmaceuticals Receives ANDA Approval for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg

Tuesday, March 5, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MUMBAI, March 5, 2019 /PRNewswire/ --

Glenmark Pharmaceuticals Inc., USA (Glenmark)

has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis®1 HCT Tablets,
of Boehringer Ingelheim Pharmaceuticals, Inc. 

     (Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )

According to IQVIATM sales data for the 12 month period ending January 2019, the Micardis® HCT Tablets market2 achieved annual sales of approximately $40.6 million*.

Glenmark's current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

About Glenmark Pharmaceuticals  

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the U.S. and Western European markets. The API business sells its products in over 80 countries, including the U.S., various countries in the EU, South America and India.

1All brand names and trademarks are the property of their respective owners

2Market includes brand and all available therapeutic equivalents

*IQVIATM National Sales Perspectives: Retail & Non-Retail, January 2019

Media Contact: Isha Trivedi corpcomm@glenmarkpharma.com +91-22-40189801 Glenmark Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store